期刊论文A first-in-class αPD-1/αVEGF/IL-2v tri-specific fusion protein demonstrates promising anti-tumor efficacy in immune checkpoint inhibitor-resistant tumor models复制

DOI:复制

文献链接:复制

其他信息:

S Cho, JE Park, Y Jung, H Bang, J Heo, S Kang…
Cancer …, 2025
aacrjournals.org
Immune checkpoint inhibitors (ICIs), including anti-PD (L) 1 monoclonal antibodies, have been widely approved and used for various cancer types. However, the response rate to ICIs is limited to certain cancer types, largely attributed to the absence or low presence of immune cells within the tumor microenvironment (TME). αVEGF antibodies not only facilitate immune cell infiltration into tumors but also improve the immunosuppressive conditions of the TME. Notably, the combination of αPD-1 and αVEGF antibodies and αPD-1/αVEGF …